6 completed, 3 active not recruiting, 2 unknown, 1 withdrawn. 4 Early Phase 1, 3 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 3.
Follow Stage III Primary Peritoneal Cancer AJCC v7: new trials by email Literature Review of Stage III Primary Peritoneal Cancer AJCC v7 trials Research Report on Stage III Primary Peritoneal Cancer AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Paclitaxel, Ruxolitinib Phosphate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Completed | NRG Oncology | 147 | 2016-11-14 | 2025-05-25 |
| Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration - Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7 | Not applicable | Withdrawn | Rutgers, The State University of New Jersey | 2016-07-27 | 2021-04-19 | |
| Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) Carboplatin, Durvalumab, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 18 | 2016-07-06 | 2026-06-11 |
| Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 31 | 2016-07-05 | 2026-07-07 |
| Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2016-02-04 | 2026-10-06 |
| Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, BMN 673 - Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 4 | 2015-06-02 | 2022-02-24 |
| Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Early Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2014-08-25 | 2024-12-13 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Carboplatin, Cisplatin, Gemcitabine Hydrochloride - FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer | Phase 1 | Active not recruiting | City of Hope Medical Center | 40 | 2014-05-19 | 2026-03-05 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 32 | 2012-03-09 | 2019-08-29 |
| Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Assessment of Therapy Complications, Carboplatin, Filgrastim - Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Unknown | Gynecologic Oncology Group | 290 | 2011-08-15 | 2021-09-30 | |
| Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Assessment of Therapy Complications, Medical Chart Review, Quality-of-Life Assessment - Anxiety, Fatigue | Unknown | Gynecologic Oncology Group | 103 | 2011-04-12 | 2019-03-12 | |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
Fallopian Tube Neoplasms (11) · Ovarian Neoplasms (2) · Anxiety Disorders (1) · Brenner Tumor (1) · Carcinoma (1) · Endometrial Neoplasms (1) · Fatigue (1) · Nausea (1) · Neurotoxicity Syndromes (1) · Uterine Cervical Neoplasms (1) · Vomiting (1)
Adnexal Diseases (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genital Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Neoplasms (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Fallopian Tube Diseases (11) · Neoplasms by Site (11) · Endocrine System Diseases (3) · Gonadal Disorders (3) · Ovarian Diseases (3) · Endocrine Gland Neoplasms (2)
Carboplatin (6) · Paclitaxel (6) · Taxes (6) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2) · Disulfides (2) · Immunoglobulin G (2) · Platinum (2) · Bevacizumab (1) · Doxorubicin (1) · Drug Therapy (1) · Filgrastim (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Propranolol (1)
M.D. Anderson Cancer Center (5) · Gynecologic Oncology Group (2) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · NRG Oncology (1) · Rutgers, The State University of New Jersey (1)
United States (12)
Shannon N Westin (2) · Vivian E von Gruenigen (2) · Amir Jazaeri, MD (1) · Charles N Landen (1) · Joan L Walker (1) · Kunle Odunsi (1) · Lois M Ramondetta (1) · Shannon Westin (1) · Sharon Manne (1) · Thanh Dellinger (1)
PMID 32379297, PMID 31002578, PMID 35357903, PMID 38776484, PMID 39151421
P30CA016672 (2), U10CA101165 (2), U10CA180868 (2), P30CA015704 (1), P30CA072720 (1), P50CA083639 (1), U01CA154967 (1), U10CA027469 (1)